Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026)

Capricor Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 2820.64% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $250.3 million (up 66.29% YoY), while the FY2025 annual figure was $248.9 million, up 62.92% from the prior year.
• Cash from Financing Activities was $1.5 million for Q1 2026 at Capricor Therapeutics, down from $248.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $248.8 million in Q4 2025 to a low of $3895.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $25.5 million across 5 years, with a median of $1.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 58699.59% in 2024, then slumped 99.99% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $2.9 million in 2022, then jumped by 685.45% to $23.2 million in 2023, then soared by 250.01% to $81.1 million in 2024, then soared by 206.85% to $248.8 million in 2025, then slumped by 99.41% to $1.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.5 million (Q1 2026), $248.8 million (Q4 2025), and $6950.0 (Q3 2025), per Business Quant data.